CYP2D6 Experiment CSV JSON

In Vivo Interaction Study

CYP2D6 Experiment

Increased systemic exposure was detected.

debrisoquine

  • CYP2D6 4173631

Results

Table 1

Sample Compound measured Measurement Value Study sequence Additional information N replicates

Experimental Conditions

Probe cocktail study
Fixed-sequence
Multiple dosing

Population

Females
Healthy volunteers
Males

Nonsmokers

CYP2D6 ultra-rapid metabolizer

12

(6 females) (age, mean ± SD = 24 ± 3.0 years; weight, 69.3 ± 14.2 kg)

Pharmacokinetic (PK) Sampling Information

8 hours

Drug or Natural Product Administration

Object Administration — debrisoquine

Oral

solution

4 mg

once

twice in 28 day trial

Precipitant Administration — goldenseal root extract

Oral

capsule

2700 mg

three times daily

28 days

Natural Product Characteristics

Wild Oats Markets, Inc. Boulder, CO.

not specified

Pharmacodynamics (PD) & Adverse Events

Gastrointestinal disorders 35700000
General disorders and administration site conditions 35800000

Headache (4 of 12 subjects) and nausea (3 of 12 subjects)